311 related articles for article (PubMed ID: 28666704)
1. Systemic and tissue-specific effects of aliskiren on the RAAS and carbohydrate/lipid metabolism in obese patients with hypertension.
Engeli S; May M; Nussberger J; Danser AHJ; Dole WP; Prescott MF; Dahlke M; Stitah S; Pal P; Boschmann M; Jordan J
J Am Soc Hypertens; 2017 Aug; 11(8):488-497. PubMed ID: 28666704
[TBL] [Abstract][Full Text] [Related]
2. Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients.
Boschmann M; Nussberger J; Engeli S; Danser AH; Yeh CM; Prescott MF; Dahlke M; Jordan J
J Hypertens; 2012 Mar; 30(3):561-6. PubMed ID: 22278138
[TBL] [Abstract][Full Text] [Related]
3. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine.
Nussberger J; Aubert JF; Bouzourene K; Pellegrin M; Hayoz D; Mazzolai L
Hypertension; 2008 May; 51(5):1306-11. PubMed ID: 18391092
[TBL] [Abstract][Full Text] [Related]
4. Effects of Aliskiren Monotherapy versus Amlodipine Monotherapy in Hypertensive Patients with Obesity or Type 2 Diabetes Mellitus.
Seki Y; Morimoto S; Kimura S; Takano N; Yamashita K; Bokuda K; Sasaki N; Watanabe D; Ichihara A
Kidney Blood Press Res; 2023; 48(1):688-700. PubMed ID: 37866351
[TBL] [Abstract][Full Text] [Related]
5. Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-A(y) mice.
Iwai M; Kanno H; Tomono Y; Inaba S; Senba I; Furuno M; Mogi M; Horiuchi M
J Hypertens; 2010 Jul; 28(7):1471-81. PubMed ID: 20543712
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
Athyros VG; Mikhailidis DP; Kakafika AI; Tziomalos K; Karagiannis A
Expert Opin Pharmacother; 2007 Apr; 8(5):529-35. PubMed ID: 17376010
[TBL] [Abstract][Full Text] [Related]
7. Effects of antihypertensive therapy on glucose, insulin metabolism, left ventricular diastolic dysfunction and renin system in overweight and obese hypertensives.
De Rosa ML; Musella F; Ilardi F; D'Amore C; Luciano R; Maresca F
J Renin Angiotensin Aldosterone Syst; 2014 Jun; 15(2):196-204. PubMed ID: 23396551
[TBL] [Abstract][Full Text] [Related]
8. Greater reductions in plasma aldosterone with aliskiren in hypertensive patients with higher soluble (Pro)renin receptor level.
Bokuda K; Morimoto S; Seki Y; Yatabe M; Watanabe D; Yatabe J; Ando T; Shimizu S; Itoh H; Ichihara A
Hypertens Res; 2018 Jun; 41(6):435-443. PubMed ID: 29618841
[TBL] [Abstract][Full Text] [Related]
9. Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
Jordan J; Engeli S; Boye SW; Le Breton S; Keefe DL
Hypertension; 2007 May; 49(5):1047-55. PubMed ID: 17353513
[TBL] [Abstract][Full Text] [Related]
10. Long-term antihypertensive effects of aliskiren, a direct renin inhibitor, in chronic hemodialysis patients.
Ishimitsu T; Ohta S; Ohno E; Takahashi T; Numabe A; Okamura A; Ohba S; Hashimoto A; Matsuoka H
Ther Apher Dial; 2013 Oct; 17(5):524-31. PubMed ID: 24107281
[TBL] [Abstract][Full Text] [Related]
11. [The future of renin inhibition].
Uresin AY; Baran E
Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
[TBL] [Abstract][Full Text] [Related]
12. Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension.
Moniwa N; Varagic J; Ahmad S; VonCannon JL; Simington SW; Wang H; Groban L; Brosnihan KB; Nagata S; Kato J; Kitamura K; Gomez RA; Lopez ML; Ferrario CM
Hypertension; 2013 Feb; 61(2):417-24. PubMed ID: 23232645
[TBL] [Abstract][Full Text] [Related]
13. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
14. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
Dalla Vestra M; Simioni N; Masiero A
Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
[TBL] [Abstract][Full Text] [Related]
15. Chronic renin inhibition with aliskiren improves glucose tolerance, insulin sensitivity, and skeletal muscle glucose transport activity in obese Zucker rats.
Marchionne EM; Diamond-Stanic MK; Prasonnarong M; Henriksen EJ
Am J Physiol Regul Integr Comp Physiol; 2012 Jan; 302(1):R137-42. PubMed ID: 22049232
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome.
Krone W; Hanefeld M; Meyer HF; Jung T; Bartlett M; Yeh CM; Rajman I; Prescott MF; Dole WP
J Hum Hypertens; 2011 Mar; 25(3):186-95. PubMed ID: 20376075
[TBL] [Abstract][Full Text] [Related]
17. Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading.
Yoshida S; Ishizawa K; Ayuzawa N; Ueda K; Takeuchi M; Kawarazaki W; Fujita T; Nagase M
Clin Exp Nephrol; 2014 Aug; 18(4):593-9. PubMed ID: 24154707
[TBL] [Abstract][Full Text] [Related]
18. Aliskiren reduces body-weight gain, adiposity and plasma leptin during diet-induced obesity.
Stucchi P; Cano V; Ruiz-Gayo M; Fernández-Alfonso MS
Br J Pharmacol; 2009 Oct; 158(3):771-8. PubMed ID: 19694726
[TBL] [Abstract][Full Text] [Related]
19. Direct renin inhibitor ameliorates insulin resistance by improving insulin signaling and oxidative stress in the skeletal muscle from post-infarct heart failure in mice.
Fukushima A; Kinugawa S; Takada S; Matsumoto J; Furihata T; Mizushima W; Tsuda M; Yokota T; Matsushima S; Okita K; Tsutsui H
Eur J Pharmacol; 2016 May; 779():147-56. PubMed ID: 26988296
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
Nussberger J; Wuerzner G; Jensen C; Brunner HR
Hypertension; 2002 Jan; 39(1):E1-8. PubMed ID: 11799102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
